Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Aliaxin FL** is a sterile, viscoelastic monophasic gel dermal filler containing **cross-linked hyaluronic acid** at a concentration of 25 mg/mL, buffered with phosphate and water for injection[1][3][4][5]. It is primarily designed to treat **fine lines** and perform **lip enhancements**, restoring subtle volume, correcting minor asymmetries, and improving definition, especially in the vermillion border of the lips[1][3][5][7]. The hyaluronic acid is ultra-pure and produced via patented bio-fermentation of Streptococcus Zooepidemicus, characterized by high tissue integration, stability, and a low percentage of cross-linking agent BDDE, offering safety and minimal residue[4]. The mechanism of action is the **physicochemical restoration of volume and hydration** through injection into the superficial to mid-dermis or labial mucosa, with biocompatibility and biodegradability ensuring transient effects lasting approximately 6–12 months[1][3]. No allergy testing is needed, and adverse reactions are minimal and transient; the product is CE-marked and produced under GMP and ISO certification.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aliaxin FL.